Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib as Adjuvant Therapy in Resected EGFR-Mutant Early-Stage NSCLC
ChiCTR2200063184Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 3-year disease-free survival. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200063184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063184.